Physician profile
Joseph J Koenigsmark
NPI 1437214731
$3,346.34
in general payments reported to CMS, 2019-2025
24 companies · $696 in 2025
The $696 reported for 2025 was more than what 86% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $406 · 2021: $372 · 2022: $545 · 2023: $521 · 2024: $569 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $684.06 | 2019-2025 | Rexulti |
| Abbvie INC. | $624.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $412.80 | 2022-2025 | Caplyta |
| Orexo US, INC. | $408.75 | 2019-2025 | Zubsolv |
| Indivior INC. | $270.05 | 2020-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $195.97 | 2020-2023 | Hetlioz |
| Gilead Sciences, INC. | $106.21 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Mdd US Operations, LLC | $73.59 | 2020 | |
| Neurocrine Biosciences, INC. | $60.30 | 2022-2024 | Ingrezza |
| Lilly USA, LLC | $50.83 | 2020-2021 | |
| Braeburn INC. | $48.91 | 2024 | Brixadi |
| Amgen INC. | $42.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.53 | 2022 | |
| Axsome Therapeutics, INC. | $38.34 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.87 | 2022 | |
| Almatica Pharma LLC | $36.05 | 2024-2025 | Loreev Xr |
| Uswm, LLC | $20.01 | 2022 | |
| Lundbeck LLC | $19.92 | 2021 | |
| Alkermes, INC. | $17.58 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.12 | 2023 | Qelbree |
| Corium, LLC | $14.05 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $13.90 | 2024 | Quviviq |
| Tris Pharma INC | $13.10 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Koenigsmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.